HALTing PKD progression—revival of blood pressure control
Crossref DOI link: https://doi.org/10.1038/nrneph.2014.241
Published Online: 2014-12-16
Published Print: 2015-03
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Benzing, Thomas
Text and Data Mining valid from 2014-12-16
Article History
First Online: 16 December 2014
Competing interests
: T.B. receives speaker honoraria from Hexal, Novartis and Otsuka.